Stocks Health care BJDX

NASDAQ · Health care

Bluejay Diagnostics, Inc. (BJDX)

It posted a net loss of $7.3M. In fiscal 2025 capital spending exceeded operating cash flow by $6.2M. At June 30, 2026 it held $9.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

What Bluejay Diagnostics, Inc. does

Bluejay Diagnostics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker BJDX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Bluejay Diagnostics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 8, 2026
   Material agreement 8-K
2. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
3. August 13, 2026
   Passive stake (5% or more) SCHEDULE 13G
4. August 13, 2026
   Investor disclosure 8-K
5. August 12, 2026
   Employee stock plan registration S-8
6. August 12, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$1.12 versus -$5.64.
7. July 22, 2026
   Investor disclosure 8-K
8. June 26, 2026
   Securities offering prospectus 424B3
9. June 17, 2026
   Shelf registration to sell securities S-3
10. June 9, 2026
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 18, 2026. Insider transactions on SEC

Insider trades

What the people running Bluejay Diagnostics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $96.7K and sold $48.9K worth of shares in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BJDX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: NorthStrive Fund II LP 0% (June 2, 2026); Braeden Lichti 0% (June 2, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 132,577 shares in total, about $122.1K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BJDX

What does Bluejay Diagnostics, Inc. do?

Bluejay Diagnostics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker BJDX.

Is Bluejay Diagnostics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $7.3M.

When did Bluejay Diagnostics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 8, 2026.

Similar companies

Compare BJDX with

Compare BJDX with any company

Follow BJDX

Get an email when Bluejay Diagnostics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BJDX: get an email when it files

Where the numbers come from

Financial figures are the values Bluejay Diagnostics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.